About
AgNovos Bioscience is a medical technology company founded in 2012 by Dr. James Howe, focusing on innovative therapies for bone diseases, particularly osteoporosis. Headquartered in New York City, with operations in Rockville, Maryland, the company employs between 51 and 200 people and fosters a culture of tenacity and innovation. The flagship product, OSSURE™ Local Osteo-Enhancement Procedure (LOEP) kit, assists surgeons in addressing bone loss due to osteoporosis. AgNovos is conducting the RESTORE clinical study to evaluate the OSSURE LOEP's effectiveness in reducing secondary hip fractures. Additionally, the AGN1 LOEP SV kit, designed for treating painful vertebral compression fractures, has received Breakthrough Device designation from the U.S. FDA. The company is also running the CONFIRM clinical study to further validate the AGN1 LOEP's safety and efficacy. AgNovos aims to enhance patient outcomes by improving bone strength and reducing fracture risk, ultimately helping patients maintain their mobility and quality of life.
Technologies
Keywords
Company Information
-
Employees 44
-
Founded 2012
-
Annual Revenue $13952000
-
Total Funding $44849283
Location
7301 Calhoun Place, Derwood, Maryland, United States, 20855
